HC Wainwright Brokers Lift Earnings Estimates for Janux Therapeutics, Inc. (NASDAQ:JANX)

Posted by Defense World Staff on Aug 12th, 2023

Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Equities research analysts at HC Wainwright raised their Q3 2023 earnings per share (EPS) estimates for Janux Therapeutics in a report issued on Wednesday, August 9th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.50) for the quarter, up from their previous forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($1.99) EPS, Q1 2024 earnings at ($0.55) EPS, Q2 2024 earnings at ($0.60) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.74) EPS and FY2024 earnings at ($2.55) EPS.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.07. Janux Therapeutics had a negative return on equity of 21.22% and a negative net margin of 862.89%. The firm had revenue of $2.05 million during the quarter, compared to the consensus estimate of $1.69 million.

Separately, Wedbush restated an “outperform” rating and set a $24.00 price target on shares of Janux Therapeutics in a report on Thursday.

View Our Latest Analysis on Janux Therapeutics

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX opened at $12.58 on Friday. Janux Therapeutics has a 1-year low of $10.00 and a 1-year high of $23.64. The business has a fifty day moving average price of $12.64 and a 200-day moving average price of $14.24. The company has a market capitalization of $580.44 million, a PE ratio of -7.72 and a beta of 1.52.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 495,008 shares of Janux Therapeutics stock in a transaction that occurred on Wednesday, July 19th. The stock was bought at an average cost of $12.46 per share, for a total transaction of $6,167,799.68. Following the acquisition, the director now owns 8,117,246 shares of the company’s stock, valued at $101,140,885.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 35.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its holdings in Janux Therapeutics by 149.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after buying an additional 2,003 shares in the last quarter. Barclays PLC increased its holdings in Janux Therapeutics by 533.0% in the 4th quarter. Barclays PLC now owns 4,608 shares of the company’s stock worth $61,000 after buying an additional 3,880 shares in the last quarter. Citigroup Inc. increased its holdings in Janux Therapeutics by 935.2% in the 2nd quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock worth $69,000 after buying an additional 5,228 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in Janux Therapeutics in the 3rd quarter worth about $103,000. Finally, SG Americas Securities LLC bought a new stake in Janux Therapeutics in the 4th quarter worth about $104,000. 82.83% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.